Oxygenta Pharma Closes Trading Window Until Post-Q2 FY27 Results

Oxygenta Pharmaceutical Ltd has announced the closure of its trading window for all designated persons, their immediate relatives, and connected persons. This closure is effective from July 1, 2026, and will remain in effect until 48 hours after the declaration of the audited financial results for the quarter ending June 30, 2026 (Q2 FY27). The company will schedule a Board Meeting to consider and approve these financial results. This measure is in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct to prevent insider trading.